

# Gastric, Esophageal, and Gastroesophageal Junction Cancer (Adenocarcinoma) Pathways

Patient Name: \_\_\_\_\_ Date of Birth: \_\_\_\_\_

Member Number: \_\_\_\_\_ Treatment Start Date: \_\_\_\_\_

ICD-10 Code: \_\_\_\_\_ Pathology: \_\_\_\_\_

Stage: \_\_0\_\_ IA \_\_ IB \_\_ IIA \_\_ IIB \_\_ IIIA \_\_ IIIB \_\_ IIIC \_\_ IV \_\_ Recurrent

Line of Treatment: \_\_ Neoadjuvant/Pre-Op \_\_ Adjuvant/Post-Op \_\_ First Line \_\_ Second Line \_\_ Third Line \_\_ Third Line+

ECOG Performance Status: \_\_0\_\_ 1 \_\_2\_\_ 3 \_\_4

Is the patient going to have surgery? \_\_Yes\_\_ No

Is the patient going to have radiation? \_\_Yes\_\_ No

## Primary therapy | Resectable and unresectable disease

Cisplatin (Platinol) and fluorouracil (5FU)

Fluorouracil (5FU) and cisplatin (Platinol) with concurrent radiation therapy (RT)

Paclitaxel (Taxol) and carboplatin (Paraplatin) with concurrent radiation therapy (RT)

## Post-operative treatment

Fluorouracil (5FU) and leucovorin with concurrent radiation therapy (RT)

## Recurrent/metastatic or locally advanced/inoperable disease | HER2 Negative | First line of therapy (1<sup>st</sup> line)

Cisplatin (Platinol) and fluorouracil (5FU)

Fluorouracil (5FU) and irinotecan (Camptosar)

FLO / FOLFOX: fluorouracil (5FU), leucovorin, and oxaliplatin (Eloxatin)

FLP: fluorouracil (5FU), leucovorin, and cisplatin (Platinol)

## Recurrent/metastatic or locally advanced/inoperable disease | HER2 Positive | First line of therapy (1<sup>st</sup> line)

Cisplatin (Platinol), fluorouracil (5FU), and trastuzumab (Herceptin)

## Recurrent/metastatic or locally advanced/inoperable disease | Second line of therapy (2<sup>nd</sup> line)

Irinotecan (Camptosar)

Paclitaxel (Taxol)

Note: Pathway lists are solely for the purpose of eligibility for enhanced reimbursement and are independent of specific health plan medical policy coverage criteria. Health plan medical policy/clinical guidelines should be consulted to determine whether proposed services will be covered.